

11. REFERENCES

Adachi, S., Kotani, K., Shimizu, T., Tanaka, K., Shimizu, T. and Okada, K., Asymptomatic fascioliasis, *Journal of Internal Medicine*, 44, 1013-1015, 2005.

Adam, I., Elwasila, E. and Homeida, M., Is praziquantel therapy safe during pregnancy? *Annals of Tropical Medicine and Parasitology*, 98, 540-543, 2004.

Adam, I., Elwasila, E. and Homeida, M., Praziquantel for the treatment of schistosomiasis mansoni during pregnancy. *Annals of Tropical Medicine and Parasitology*, 99, 37-40, 2005.

Aditya, N.P., Patankar, S., Madhusudhan, B., Murthy, R.S. and Souto, E.B., Artemether-loaded lipid nanoparticles produced by modified thin-film hydration: Pharmacokinetics, toxicological and in vivo anti-malarial activity. *European Journal of Pharmaceutical Sciences*, 40, 448-55, 2010.

Aditya, N.P., Waree, T., Patankar, S., Madhusudhan, B. and Souto, E.B., Curcuminoids-loaded lipid nanoparticles: Novel approach towards malaria treatment, *Colloids and Surfaces B. Biointerfaces.*, 81, 263–273, 2010.

Akbarieh M., Besner JG., Galal A. and Tawashi R., Liposomal delivery system for the targeting and controlled release of praziquantel. *Drug Dev. Ind. Pharm.* 18, 303-317, 1992.

Alex, M.R., Chackoa, A., Josea, A.J. and S.Souto, E.B., Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting, *Eur. J. Pharm. Sci.*, 42(1-2), 11–18, 2011.

Almeida, A.J., Runge, S., Müller, R.H., Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parameters, *International Journal of Pharmaceutics*, 149, 255-265, 1997.

Almeida, A.J. and Souto, E.B., Solid lipid nanoparticles as a drug delivery system for peptides and proteins. *Advance Drug Delivery*, 59, 478–490, 2007.

Andrews, P., A summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action, *Drug Research*, 31, 538–541, 1981.

Andrianov, A.K. and Payne, L.G., Polymeric carriers for oral uptake of microparticulates, *Adv. Drug Deliv. Rev.*, 34, 155–170 1998

Ansari, K.A., Torne, S.J., Vavia, P.R., Trotta, F. and Cavalli, R., Paclitaxel loaded nanosponges, in-vitro characterization and cytotoxicity study on MCF-7 cell line culture, *Current Drug Delivery*, 8(2), 194-202, 2011.

Baert, L., Klooster, G.V. and Dries, W. et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. *Eur. J. Pharm. Biopharm.* 72 (3), 502–508, 2009.

Bale, J.F., Cysticercosis, *Current Treatment Options in Neurology*, 2, 355–360, 2000.

Bargoni, A., Cavalli, R., Caputo, O., Fundarò, A., Gasco, M.R. and Zara, G.P., Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats, *Journal of Pharmacy Research*, 15, 745-50, 1998.

Barratt, G., Colloidal drug carriers: achievements and perspectives. *Cell Mol. Life Sci.* 60, 21–37, 2003

Becket, G., Schep, L.J. and Tan, M.Y., Improvement of the in vitro dissolution of praziquantel by complexation with α -, β - and γ -cyclodextrins, *International Journal of Pharmaceutics*, 179, 65–71, 1999.

Bennett, J.L., Day, T., Liang, F.T., Ismail, M. and Farghaly, A., The development of resistance to anthelmintics: a perspective with an

emphasis on the antischistosomal drug praziquantel, *Experimental Parasitology*, 87, 260-267, 1997.

Bittencourt, P.R., Gracia, C.M., Martins, R., Fernandes, A.G., Diekmann, H.W. and Jung, W., Phenytoin and carbamazepine decreased oral bioavailability of praziquantel, *Neurology*, 42, 492-496, 1992.

Bittencourt, P.R.M., Garcia, C.M., Gorz, A.M. and Oliveira, T.V., High dose praziquantel for neurocysticercosis: serum and CSF concentrations, *Acta Neurological Scandinavica*, 82, 28-33, 1990.

Botros, S., Sayed, H., Amer, N., El-Ghannam, M., Bennett, J.L. and T.A., Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt, *International Journal of Parasitology*, 35, 7-91, 2005.

Brigger, I., Duberne, C., Couvreur, P., Nanoparticles in cancer therapy and diagnosis, *Advanced Drug Delivery Reviews*, 54, 631-651, 2002.

Bunjes, H., Koch, M.H.J., Saturated phospholipids promote crystallization but slow down polymorphic transitions in triglyceride nanoparticles, *Journal of Control Release*, 107, 229-243, 2005.

Bunjes, H., Westesen, K. and Koch, M. H. J., Crystallization tendency and polymorphic transitions in triglyceride nanoparticles, *International Journal of Pharmaceutics*, 129, 159-173, 1996.

Bunjes, H., Koch, M.H.J., Westesen, K., Influence of emulsifiers on the crystallization of solid lipid nanoparticles, *Journal of Pharmaceutical Sciences*, 92, 1509-1520, 2003.

Bushara, H.O., Majid, B.Y., Majid, A.A., Khitma, I., Gameel, A.A., Karib, E.A., Hussein, M.F. and Taylor, M.G., Observations on cattle schistosomiasis in the Sudan, a study in comparative medicine. V. The effect of praziquantel therapy on naturally acquired resistance to *Schistosoma bovis*, *American Journal of Tropical Medicine and Hygiene*, 32, 1370-1374, 1983.

Bygott JM. and Chiodini PL., Praziquantel: neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease? *Acta Trop*111(2):95-10, 2009

Caffrey, C.R., Chemotherapy of schistosomiasis: present and future, *Current Opinion Chemical Biology*, 11(4), 433–439, 2007.

Caliph, S.M., Charman, W.N. and Porter, C.J.H., Effect of short-, medium-, and long-chain fatty acid based vehicles on the absolute oral bioavailability and intestinal lymphatics transport of Halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats, *Journal of Pharmaceutical Science*, 89, 1073-84, 2000.

Castro, N., Gonzalez-Esquivel, D. F., Lopez, M. and Jung, H., Comparative analysis of the influence of food and cimetidine in plasma levels of praziquantel, *Revista Investigacion Clinica*, 55, 655-661, 2003.

Castro, N., Jung, H., Medina, R., Gonzalez-Esquivel, D., Lopez, M. and Sotelo, J., Interaction between grapefruit juice and praziquantel in humans, *Antimicrobial Agents of Chemotherapy*, 46, 1614-1616, 2002.

Cavalli, R., Caputo, O., Carlotti, M., Trotta, M., Scarnecchia, C. and Gasco. M.R., Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles, *International Journal of Pharmaceutics*, 148, 47–54, 1997.

Chakraborty, S., Shukla, D., Mishra, B. and Singh, S., Lipid –an emerging platform for oral delivery of drugs with poor bioavailability, *European Journal of Pharmaceutics and Biopharmaceutics*, 73,1–15, 2009.

Chattopadhyay, P., Shekunov, B.Y., Yimb, D., Cipolla, D., Boyd, B. and Farr. S., Production of solid lipid nanoparticles suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system, *Advanced Drug Delivery Reviews*, 59, 444–453, 2007.

Chen, M.G., Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience. *Acta Trop.*96, 168–176, 2005.

Cheng, L., Lei, L. and Guo, S.R., In vitro and in vivo evaluation of praziquantel loaded implants based on PEG/PCL blends, *International Journal of Pharmaceutics*, 387,129–138, 2010.

Cheng, M.G., Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China, *Acta Tropica*, 96(2-3), 168-76, 2005.

Chitsulo, L., Engels, D., Montrosor, A. and Savioli, L., The global status of schistosomiasis and its control, *Acta Tropica*, 77, 41–51, 2000.

Cioli, D. and Pica-Mattocchia, L., Praziquantel, *Parasitol. Res.*, 90(Supp 1),S3-9, 2003.

Clark, M.A., Japson, M.A. and Hirst, B.H., Exploiting M cells for drug and vaccine drug delivery, *Advance Drug Delivery Review* ,50,81-106, 2001.

Cobo, F., Yarnoz, C., Sesma, B., Fraile, P., Aizcorbe, M., Trujillo, R., Diaz-de-Liaño, A. and Ciga, M.A., Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatidosis caused by *Echinococcus granulosus*, *Tropical Medicine International Health*, 3, 462–466, 1998.

Cong, TT., Faivre, V., Nguyen, TT. , Heras, H., Pirot, F., Walchshofer, N., Sarciron, M. and Falson, F., Study on the hydatid cyst membrane: Permeation of model molecules and interactions with drug-loaded nanoparticles, *Int J Pharm* 353: 223–232, 2008

Costa, P., Lobo, JMS., Modelling and comparison of dissolution profiles, *European Journal of Pharmaceutical Sciences*, 13, 123-133, 2001.

Dahan, A., and Hoffman, A., Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs, *European Journal of Pharmaceutical Sciences*, vol.24, pp. 381–388, 2005.

Darandale, S. and Vavia, P., Cyclodextrin-based nanosponges of curcumin, formulation and physicochemical characterization, *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, 75 (3-4), 315-322, 2012.

Das, S., Ng, W.K., Kanaujia, P., Kim, S. and Tan, R.B.H., Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: Effects of process variables, *Colloids and Surface B: Biointerfaces*, 88, 483–489, 2011.

Date, A.A., Joshi, M.D. and Patravale, V.B., Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles, *Advance Drug Delivery Review*, 59,505-21, 2007.

Dayan, A.D., Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics, *Acta Tropica*, 86, 141-159, 2003.

Dixon, B.R. and Arai, H.P., Anthelmintic-induced destrbilation and its influence on calculated drug efficacy in *Hymenlepsis diminuta* infections in rats, *Journal of parasitology*, 77(5), 769-774, 1991.

Doenhoff, M.J. and Pica-Mattoccia, L., Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance, *Expert Review of Anti-Infective Therapy*, 4,199-210, 2006.

Dollery, C.T., Praziquantel. In: *Therapeutic Drugs*, Churchill Livingstone, Edinburgh, vol 1, second edition, pp. M184- P188, 1999.

Duchêne, D., Ponchel, G., Bioadhesion of solid oral dosage forms, why and how? *Eur. J. Pharm. Biopharm.* 44 (1) 15–23, 1997.

El-Arini, S.K. and Leuenberger, H., Dissolution properties of praziquantel-PVP systems, *Pharmaceutica Acta Helvetiae*, 73, 89–94, 1998.

El-Arini, S.K. and Leuenberger, H., Dissolution properties of praziquantel- β -cyclodextrin systems, *Pharmaceutical Development and Technology*, 1, 307–315, 1996.

EMA-European Medicines Evaluation Agency, 1996, Praziquantel Summary Report vy CVMP. EMA/ MRL/ 141/ 96 September 1996, EMA, London.

Florence, A.T., Hillery, A.M., Hussain, N., and Jani, P.U., Nanoparticles as carriers for oral peptide absorption: studies on particles uptake and fate, *Journal of Controlled Release*, 36, 39–46, 1995.

Freitas, X., and Muller, R.H., Spray drying of solid lipid nanoparticles (SLN), *European Journal of Pharmaceutics and Biopharmaceutics*, 46, 145-151, 1998.

Frohberg, H., Results of toxicological studies on praziquantel, *Arzneimittelforschung*, 34, 1137-1144, 1984.

Frohberg, H., The toxicological profile of praziquantel in comparison to other anthelmintic drugs, *Acta. Leiden.*, 57, 201-215, 1989.

Gao, F., Zhang, Z., Bu, H., Huang, Y., Gao, Z., Shen, J., Zhao, C. and Li, Y., Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism, *Journal of Controlled Release*, 149, 168–174, 2011.

Gasco, M.R., Method for producing solid lipid micro-spheres having narrow size distribution, US Patents 5250236, 1993.

Gemmell, M.A., Johnstone, P.D. and Oudemans, G., The effect of praziquantel on *Echinococcus granulosus*, *Taenia hydatigena* and *Taenia*

ovis infections in dogs, *Research in Veterinary Science*, 23, 121–123, 1977.

Giorgi, M., Meucci, V., Vaccaro, E., Mengozzi, G., Giusiani, M., Soldani, G. and Bregani, Effects of liquid and freeze-dried grapefruit juice on the pharmacokinetics of praziquantel and its metabolite 4'-hydroxy praziquantel in beagle dogs, *Pharmacological Research*, 47, 87-92, 2003.

Godawska-Matysik, A., Pekala, E. and Kiec-Kononowicz, K., The research on biotransformation of praziquantel, *Acta Poloniae Pharmaceutica*, 61(Suppl), 75-78, 2004.

Gokce, E.H., Sandri, G., Bonferoni, M.C., Rossi, S., Ferrari, F., Güneri, T. and Caramella, C., Cyclosporine A loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity, *International Journal of Pharmaceutics*, 364, 76-86, 2008.

Gonnert, R. and Andrews, P., Praziquantel, a new broad-spectrum antischistosomal agent. *Z. Parasitenkd.* 52, 129–150, 1997.

Gonzalez-Esquivel, D., Rivera, J., Castro, N., Yepez-Mulia, L. and Jung-Cook, H., In vitro characterization of some biopharmaceutical properties of praziquantel, *International Journal of Pharmaceutics*, 295, 93-99, 2005.

Gottstein, B. and Reichen, J., Echinococcosis/hydatidosis, Cook GC, Zumla A, eds. *Manson's Tropical Diseases*, London: W. B. Saunders, Elsevier Science Ltd., 1561–1582, 2003.

Greenberg, R.M., Ca²⁺ channels targets of praziquantel action? *International Journal of Parasitology*, 35, 1-9, 2005.

Greenberg, R.M., Ca²⁺ signaling, voltage-gated Ca²⁺ channels and praziquantel in flatworm neuromusculature, *Parasitology*, 131(Suppl), S97-S108, 2005.

Hanpitakpong, W., Banmairuroi, V. and Kamanikom, B., A high-performance liquid chromatographic method for determination of praziquantel in plasma, *J Pharmaceut Biomed* 36, 871–876, 2004.

Hanpitakpong, W., Banmairuroi, V., Kamanikom, B., Choemung, A. and Na-Bangchang, K., A high-performance liquid chromatographic method for determination of praziquantel in plasma, *Journal of Pharmaceutical and Biomedical Analysis*, 36(4), 871-876, 2004.

Hawley, A.E., Davis, S.S. and Illum, L., Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics, *Advance Drug Delivery Review*, 17, 129–148, 1995.

Heiati, H., Tawashi, R., Shivers, R.R. and Phillips, N.C., Solid lipid nanoparticles as drug carriers. I. Incorporation and retention of the lipophilic prodrug 3'-azido-3'-deoxythymidine palmitate, *International Journal of Pharmaceutics*, 146, 123-131, 1997.

Holm, R. and Hoest, J., Successful in silico predicting of intestinal lymphatic transfer, *International Journal of Pharmaceutics*, 272(1-2), 189-93, 2004.

Holm, R., Mullertz, A., Christensen, E., Hoy, C.E. and Kristensen, H.G., Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats, *European Journal of Pharmaceutics Science*, 14, 331–337, 2001.

Homeida, M.M., Eltom, I.A., Sulaiman, S.M., Ali, H.M. and Bennett, J.L., Tolerance of two brands of praziquantel, *Lancet*, 2(8659), 391, 1989.

Homeida, M.M., Leahy, W., Copeland, S., Ali, M.M. and Harron, D.W., Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men, *Annals of Tropical Medicine and Parasitology*, 88, 551-559, 1994.

Hotez, P.J., Molyneux, D.H., Fenwick, A., Kumaresan, J., Sachs, S.E., Sachs, J.D. and Savioli, L., Control of neglected tropical diseases, *The New England Journal of Medicine*, 357, 1018-1027, 2007.

Hou, D., Xie, C., Huang, K. and Zhu, C., The production and characteristics of solid lipid nanoparticles (SLNs). *Biomaterials.*, 24, 1781–1785, 2003.

Hrckova, G. and Velebny, S., Effect of praziquantel and liposome-incorporated praziquantel on peritoneal macrophage activation in mice infected with *Mesocestoides corti* tetrathyridia (Cestoda), *Parasitology*, 114, 475-482, 1997.

Hu, F.Q., Yang, H., Zhang, H.H. and Fang, M., Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization, *International Journal of Pharmaceutics.*, 239, 121-8, 2002.

Hu, L., Tang, X. and Cui, F., Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. *Journal of Pharmacy and Pharmacology*, 56, 1527–1535, 2004.

Hussain, N., Jaini, P.U. and Florence, A.T., Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat, *Pharmacy Research*, 14, 613-8, 1997.

Hussain, N., Jaitley, V. and Florence, A.T., Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. *Advance Drug Delivery Review*, 50, 107–142, 2001.

Ismail, M., Botros, S., Metwally, A., Williams, S., Farghaly, A., Tao, L.F., Day, T.A. and Bennet, J.L., Resistance to praziquantel: direct evidence from *Schistosoma mansoni* isolated from Egyptian villagers, *American Journal of Tropical Medicine and Hygiene*, 60, 932-935, 1999.

Jenkins, D.J., Hydatid control in Australia: where it began, what we have achieved and where to from here, *International Journal of Parasitology*, 35, 733-740, 2005.

Jenning, V. , Thunemann, A.F., and Gohla, S.H. , Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids, *International Journal of Pharmaceutics*, 199, 167–177, 2000.

Jenny, A., Merima, P., Alberto, F. and Francesco, T., Role of β - cyclodextrin nanosponges in polypropylene photooxidation, *Carbohydrate Polymers*, 86, 127-135, 2011

Jeziorski, M.C. and Greenberg, R.M., Voltage-gated calcium channel subunits from platyhelminths: Potential role in praziquantel action, *International Journal of Parasitology*, 36(6), 625–632, 2006.

Jiao, W., Cheng, F. and Qun, Q., Epidemiological evaluations of the efficacy of slow-released praziquantel-medicated bars for dogs in the prevention and control of cystic echinococcosis in man and animals, *Parasitology International*, 54, 231–236, 2005.

Joshi, M., Patravale, V., Formulation and evaluation of Nanostructured Lipid Carrier (NLC)-based gel of Valdecoxib, *Drug Development and Industrial Pharmacy*, 32,911-918, 2006.

Jung, H., Hurtado, M., Sanchez, M., Medina, T.M. and Sotelo, J., Plasma and CSF levels of albendazol and praziquantel in patients with neuroysticercosis, *Clin. Neuropharm*, 13, 559– 564, 1990.

Jung, H., Medina, R., Castro, N., Corona, T. and Sotelo, J., Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen, *Antimicrobial Agents of Chemotherapy* , 41, 1256–1259, 1997.

Kabatereine, N.B., Kemijumbi, J., Ouma, J.H., Sturrock, R.F., Butterworth. A.E., Madsen, H., Ornbjerg, N., Dunne, D.W. and Vennervald, B.J., Efficacy and side effects of praziquantel treatment in a highly endemic *Schistosoma mansoni* focus at Lake Albert, Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene, 97, 599-603, 2003.

Kamiya,S., Nozawa,Y., Miyagishima,A., Kurita,T., Sadzuka,Y. and Sonobe,T., Physical Characteristics of Freeze-Dried Griseofulvin-Lipids Nanoparticles, Chemical and Pharmaceutical Bulletin, 54, 181-184, 2006.

Khalid, A.A., Pradeep RV, Trotta F, and Roberta C., Cyclodextrin-based nanosponges for delivery of Resveratrol, In Vitro characterisation, stability, cytotoxicity and permeation Study AAPS PharmSciTech, 12(1), 279-286, 2011.

Kheir, M.M., Baraka, O.Z., el-Tom, I.A., Mukhtar, M.M. and Homieda, M.M., Effects of single-dose praziquantel on morbidity and mortality resulting from intestinal schistosomiasis, Eastern Mediterranean Health Journal, 6, 926-931, 2000.

Kheir, W.M., Elsheikh, H.A. and Hapke, H.J., The effect of praziquantel on the activities of some drug metabolizing hepatic enzymes in rabbits, Dtsch Tierarztl.Wochenschr Journal, 102, 84-86, 1995.

Kipp, J.E., The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs, International Journal of Pharmaceutics, 284, 109-122, 2004.

Kjetland, E.F., Mduluza, T., Ndhlovu, P.D., Gomo, E., Gwanzura, L., Midzi, N., Mason, P.R., Friis, H. and Gundersen, S.G., Genital schistosomiasis in women: a clinical 12-month in vivo study following treatment with praziquantel, Transactions of the Royal Society of Tropical Medicine and Hygiene, 100(8), 740-52, 2006.

Kosermayer, RW., Gurny, R., Doelker, EM., Bury, P. and Peppas, NA., Mechanism of solute release from porous hydrophilic polymers, *International Journal of Pharmaceutics*, 15, 25-35, 1983.

Kramers, P.G., Gentile, J.M., Gryseels, B.J., Jordan, P., Katz, N., Mott, K.E., Mulvihill, J.J., Seed, J.L. and Frohberg, H., International Commission for Protection Against Environmental Mutagens and Carcinogens, ICPEMC publication No. 18, Review of the genotoxicity and carcinogenicity of antischistosomal drugs; is there a case for a study of mutation epidemiology? Report of a task group on mutagenic antischistosomals, *Mutat Res*, 257(1), 49-89, 1991.

Kramers, P.G.N., Gentile, J.M., Gryseels, B.J.A.M., Jordand, P., Katz, N., Mott, K.E. , Mulvihill, J.J., Seed, J.L. and Frohberg, H., Review of the genotoxicity and carcinogenicity of antischistosomal drugs; is there a case for a study of mutation epidemiology? Report of a task group on mutagenic antischistosomals, *Mutation Research/Reviews in Genetic Toxicology*, 257, 1, 49–89, 1991.

Lala, R., Thorat, A., and Gargote, C., Current trends in β - cyclodextrin based drug delivery systems, *International Journal of Research in Ayurveda and Pharmacy*, 2(5), 1520-1526, 2011.

Leopold, G., Ungethüm, W., Groll, E., Diekmann, H.W., Nowak, H. and Wegner, D.H.G., Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes – an example of complex study covering both tolerance and pharmacokinetics, *European Journal of Clinical Pharmacology*, 14, 281–291, 1978.

Li, H.L., Zhao, X.B. ,Ma, Y.K., Zhai, G., Li, L.B. and Lou, H.X., Enhancement of gastrointestinal absorption of quercetin by solid lipidnanoparticles, *J. Control. Release*, 133(3), 238–244, 2009.

Li, S.Y., Zhao, B.K. and Wang, F.H, Yak interferon-loaded solid lipid nanoparticles for controlled release. *Research in Veterinary Science*, 88, 148–153, 2009.

Lim, S.J. and Kim, C.K., Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid, *International Journal of Pharmaceutics*, 243, 135–146, 2002.

Lima, S.F., Vieira, L.Q., Harder, A. and Kusel, J.R., Effects of culture and praziquantel on membrane fluidity parameters of adult *Schistosoma mansoni*. *Parasitology* 109 (1), 57-64, 1994.

Lindenberg, M., Kopp, S. and Dressman, J.B., Classification of orally administered drugs on the World Health Organization Model list of essential medicines according to the biopharmaceutics classification system, *European Journal of Pharmaceutical and Biopharmaceutical*, 58, 265–278, 2004.

Liu, J., and Stewart, J.T., High-performance liquid chromatography determination of praziquantel enantiomers in human serum using a reversed-phase cellulose-based chiral stationary phase and disc solid phase extraction, *Journal of Chromatography B: Biomedical Science and Application*, 692, 141-147, 1997.

Liu, L.X. and Weller, P.F., Antiparasitic drugs, *New England Journal of Medicine*, 334, 1178-1184, 1996.

Liu, Y., Wang, X., Wang, J.K. and Ching, C.B., Structural characterization and enantioseparation of the chiral compound praziquantel, *Journal of Pharmaceutical Science*, 93, 3039–3046, 2004.

Liu, Y.H., Qian, M.X., Wang, X.G., Jia, J., Wang, Q.N., Jiang, Y.F., Wang, R.Q., Yan, S.W., Chen, B.Y., Li, J.S., Qiu, Z.Y. and Shen, J.K., Comparative efficacy of praziquantel and its optic isomers in experimental therapy of

schistosomiasis japonica in rabbits, Chinese Medical Journal, 99, 935–940, 1986.

Lopes, R., Eleutério, C.V., Gonçalves, L.M.D., Cruz, M.E.M., and Almeida, A.J., Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis, European Journal of Pharmaceutical Science, 45, 442–450, 2012.

Lown, K.S., Bailey, D.G., Fontana, R.J., Janardan, S.K., Adair, C.H., Fortlage, L.A., Brown, M.B., Guo, W., and Watkins, P.B., Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression, The Journal of Clinical Investigation, 99(10), 2545-53, 1997.

Luo, Y., Chen, D., Ren, L., Zhao X., and Qin, J., Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability, Journal of Control, Release, 114, 53–59, 2006.

Mainardes, R.M., and Evangelista, R.C., PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution, International Journal of Pharmaceutics, 290, 137-144, 2005.

Mandour, M.E., el Turabi, H., Homeida, M.M., el Sadig, T., Ali, H.M., Bennett, J.L., Leahey, W.J. and Harron, D.W., Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis, Transactions of the Royal Society of Tropical Medicine and Hygiene, 84, 389-393, 1990.

Manjunath, K., and Venkateswarlu, V., Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration, Journal of Control Release, 107, 215-28, 2005.

Markoski, M.M., Trindade, E.S., Cabrera, G., Laschuk, A., Galanti, N., Zaha, A., Nader, H.B., and Ferreira, H.B., Praziquantel and albendazole damaging action on *in vitro* developing *Mesocestoides corti* (Platyhelminthes:Cestoda), Parasitol International, 55, 51-61, 2006.

Martin, R.J., Mode of action of anthelmintic drugs, *Veterinary Journal*, 154, 11-34, 1997.

Martindale - The Extra Pharmacopoeia, In: Reynolds, J.R.(Ed.), Praziquantel, 30th ed., The Pharmaceutical Press, London, 52-53, 1993.

Masimirembwa, C.M., and Hasler, J.A., Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors. *Biochem. Pharmacol.*, 48, 1779-1783, 1994.

Masimirembwa, C.M., and Hasler, J.A., Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors, *Biochemical Pharmacology*, 48:1779-1783, 1994.

Maurao, S.C., Costa, P.I., Salgado, H.R, and Gremiao, M.P., Improvement of antischistosomal activity of praziquantel by incorporation in to phosphatidylcholine-containing liposomes, *International Journal of Pharmaceutics*, 295, 157-162, 2005.

McLennan, D.N., Porter, C.J., and Charman, S.A., Subcutaneous drug delivery and the role of the lymphatics, *Drug Discovery Today Technology*, 2, 89-96, 2005.

Mduluza, T., Ndhlovu, P.D., Madziwa, T.M., Midzi, N., Zinyama, R., Turner, C.M., Chandiwana, S.K., Nyazema, N., and Hagan, P., The impact of repeated treatment with praziquantel of schistosomiasis in children under six years of age living in an endemic area for *Schistosoma haematobium* infection, *Memories do Institute Oswaldo. Cruz.*, 96(Suppl), 157-164, 2001.

Mehlhorn, H., Schmahl, G., Frese, M., Mevissen, I., Harder, A., and Krieger, K., Effects of a combination of emodepside and praziquantel on parasites of reptiles and rodents, *Parasitol Research*, 97 (Suppl 1), S65-S69, 2005.

Mehnert, W., and Mader, K., Solid lipid nanoparticles: production, characterization and applications, *Advance in Drug Delivery Review*, 47,165–196, 2001.

Meier, H., and Blaschke, G., Capillary electrophoresis mass spectrometry, liquid chromatography mass spectrometry and nanoelectrospray-mass spectrometry of praziquantel metabolites, *Journal of Chromatography B: Biomedical Science and Application*, 748, 221-231, 2000.

Meier, H., and Blaschke, G., Investigation of praziquantel metabolism in isolated rat hepatocytes, *Journal of Pharmaceutical and Biomedical Analysis*, 26, 409-415, 2001.

Mishra, A., Vuddanda and P.R., Singh, S., Intestinal Lymphatic Delivery of Praziquantel by Solid Lipid Nanoparticles: Formulation Design, In Vitro and In Vivo Studies, *Journal of Nanotechnology*, 2014, 12, 2014.

Moneghini, M., Voinovich, D., Princivalle, F., Magarotto, L., Formulation and evaluation of vinylpyrrolidone/vinylacetate copolymer microspheres with carbamazepine, 5(3), 347-53, 2000.

Morris, D.L., Richards, K.S., and Chinnery, J.B., Protoscolicidal effect of praziquantel—in-vitro and electron microscopical studies on *Echinococcus granulosus*, *Journal of Antimicrobial Chemotherapy*, 18, 687–691, 1986.

Muhlen, A.Z., Schwarz, C., and Mehnert, W., Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism, *European Journal of Pharmaceutical and Biopharmaceutics*, 45,149–155, 1998.

Müller, R.H., and Keck, C.M., Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles, *Journal of Biotechnology*, 113, 151-70, 2004.

Muller, R.H., Mader, K., and Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art, *European Journal of Pharmaceutical and Biopharmaceutics*, 50, 161–177, 2000.

Muller, R.H., Mader, K., Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art, *Eur. J. Pharm. Biopharmaceutics*, 50, 161–177, 2000.

Muller, R.H., Mehenert, W., Lucks, J.S., Solid lipid nanoparticles (SLN)—An alternative colloidal carrier system for controlled drug delivery, *European Journal of Pharmaceutical and Biopharmaceutics*, 41, 62-69, 1995.

Müller, R.H., Radtke, M., and Wissing, S.A., Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, *Advanced Drug Delivery Reviews*, 54, Suppl. 1, S131-S155, 2002.

Muller, R.H., Shegokar and R., Keck, C.M., 20 Years of Lipid Nanoparticles (SLN & NLC): Present State of Development & Industrial Applications, *Current Drug Discovery Technologies*, 8 (3), 207-227, 2011.

Muranishi, S., Fujita, T., Murakami, M., and Yamamoto, A., Potential for lymphatic targeting of peptides, *Journal of Control Release*, 46, 157-64, 1997.

Nash T.E., Human case management and treatment of cysticercosis, *Acta Tropical*, 87, 61-69, 2003.

Nema, S., Brendel, R.J., Washkuhn, R., Excipients: Parenteral Dosage Forms and Their Role, Swarbrick J. (Ed.), *Encyclopedia of Pharmaceutical Technology*, Informa Healthcare USA, Inc., New York, 1622–1645, 2007.

Noriega-Peláez, E.K., Mendoza-Muñoz, N., Ganem-Quintanar, A., Quintanar-Guerrero, D., Optimization of the emulsification and solvent displacement method for the preparation of solid lipid nanoparticles, *Drug Development and Industrial Pharmacy*, 37, 160–166, 2011.

Ohshima,H., Miyagishima,A., Kurita,T., Makino,Y., Iwao,Y., Sonobe,T., Itai,S., Freeze-dried nifedipine-lipid nanoparticles with long-term nano-dispersion stability after reconstitution, *International Journal of Pharmaceutics*, 377, 180-184, 2009.

Olds, G.R., Administration of praziquantel to pregnant and lactating women. *Acta. Tropical*, 86, 185-195, 2003.

Omar, A., Elmesallamy, Gel-S., and Eassa, S., Comparative study of the hepatotoxic, genotoxic and carcinogenic effects of praziquantel distocide & the natural myrrh extract Mirazid on adult male albino rats, *Journal of Egyptian Society of Parasitology*, 35, 313-329, 2005.

Oussoren, C., Zuidema, J., Crommelin, D.J., and Storm, G., Lymphatic uptake and biodistribution of liposomes after subcutaneous injection, influence of liposomal size, lipid composition and lipid dose, *Biochimica et Biophysica Acta*, 1328, 261–272, 1997.

Paliwal, R., Rai, S., Vaidya, B., Khatri, K., Goyal, A.K., Mishra, N., Mehta, A., and Vyas, S.P., Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery, *Nanomedicine*, 5, 184–191, 2009.

Palomares, F., Palencia, G., Ambrosio, J.R., Ortiz, A., and Jung- Cook, H., Evaluation of the efficacy of albendazole sulphoxide and praziquantel in combination on *Taenia crassiceps* cysts: in vitro studies, *Journal of Antimicrobial Chemotherapy*, 57, 482-488, 2006.

Passerini, N., Albertini, B., Perissutti, B., Rodriguez, L., Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel. *Int. J. Pharm.*, 318, 92-102, 2006.

Phillips, W.T., Klipper, R., Goins, B., Novel method of greatly enhanced delivery of liposomes to lymph nodes. *J. Pharmacol. Exp. Ther.* 295 (1), 309–313, 2000.

Pica-Mattocchia L., and Cioli D., Sex- and stage-related sensitivity of *Schistosoma mansoni* to in vivo and in vitro praziquantel treatment, *Int. J. Parasitol*, 34, 527–533 (2004).

Porter, C.J., and Charman, W.N., Intestinal lymphatic drug transport: an update, *Advance Drug Delivery*, 50, 61-80, 2001.

Putter, J., and Held, F., Quantitative studies on the occurrence of praziquantel in milk and plasma of lactating women, *European Journal of Drug Metabolism and Pharmacokinetic*, 4, 193-198, 1979.

Rao, M., Bajaj, A., Khole, I., Munjapara, G., and Trotta, F., In vitro and in vivo evaluation of b-cyclodextrin-based nanosponges of telmisartan, *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, 77 (1-4), 135-145, 2012.

Rawat, M.K., Jain, A., and Singh, S., In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats, *Journal of pharmaceutical Sciences*, 100, 2406–2417, 2011.

Rawat, M.K., Jain, A., and Singh, S., Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: *in vitro* and *in vivo* evaluation *Journal of Pharmaceutical Sciences*, 100(6), 2366–2378, 2011.

Rawat, M.K., Jain, A., Mishra, A., Muthu, M.S., Singh, S., Development of repaglinide loaded solid lipid nanocarrier: selection of fabrication method. *Current Drug Delivery*, 7, 44-50, 2010.

Reddy, L.H., and Murthy, R.S.R., Etoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation, *AAPS Pharma Science and Technology*, 6, E 158–E166, 2005.

Ribeiro, F., Coelho, P.M., Vieira, L.Q., Watson, D.G., and Kusel, J.R., The effect of praziquantel treatment on glutathione concentration in *Schistosoma mansoni*, *Parasitology*, 116, 229-236, 1998.

Rosalba, M., Roberta, C., Roberto, F., Chiara, D., Piergiorgio, P., Leigh, E., Li, S., Roberto, P., Antitumor activity of nanosponge-encapsulated Camptotecin in human prostate tumors, *Cancer Research*, 71, 4431, 2011.

Rumjanek, F.D., and Simpson, A.J.G., The incorporation and utilization of radiolabelled lipids by adult *Schistosoma mansoni* in vitro, *Molecular and Biochemical Parasitology*, 1, 31-42, 1980.

Santos, F.L., and de Faro, L.B., The first confirmed case of *Diphyllbothrium latum* in Brazil, *Memorias do Institute Oswaldo.Cruz.*, 100, 585-586, 2005.

Schantz, P.M., Parasitic zoonoses in perspective, *International Journal of Parasitology*, 3211, 61-170, 1991.

Schubert, M.A., Schicke, B.C., and Müller-Goymann, C.C., Thermal analysis of the crystallization and melting behavior of lipid matrices and lipid nanoparticles containing high amounts of lecithin, *International Journal of Pharmaceutics*, 298,242-254, 2005.

Schwarz, C., and Mehnert, W., Freeze-drying of drug free and drug loaded solid lipid nanoparticles (SLN), *International Journal of Pharmaceutics*, 157, 171-179, 1997.

Seeballuck, F., Ashford, M.B., and O'Driscoll, C.M., The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells, *Pharmacy Research*, 20, 1085-1092, 2003.

Siekmann, B., and Westesen, K., Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles, *Colloid Surface of B: Biointerfaces*, 3,159–175, 1994.

Sjostrom, B., and Bergenstahl, B., Preparation of submicron drug particles in lecithin stabilized o/w emulsions, Model studies of the precipitation of cholesteryl acetate, *International Journal of Pharmaceutics*, 88, 53-62,1992.

Smyth JD, and Barrett NJ., 1980. Procedures for testing the viability of human hydatid cysts following surgical removal especially after chemotherapy, *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 74, 849–852, 1980.

Song, K.H., Chung, S.J., and Shim, C.K., Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts, *Journal of Control. Release*, 106, 298–308, 2005.

Sotelo J., Escobedo F., Rodriguez-Carbajal J., Torres B. and Rubio-Donnadieu, F., Therapy of parenchymal brain cysticercosis with praziquantel, *New England Journal of Medicine* , 310 , 1001–1007, 1984.

Sotelo J., Torres B., Rubio-Donnadieu F., Escobedo F. and Rodriguez-Carbajal, J., Praziquantel in the treatment of neurocysticercosis: a long-term follow-up, *Neurology*, 35, 752–755, 1985.

Sotelo, J., and Jung, H., Pharmacokinetic optimisation of the treatment of neurocysticercosis, *Clinical Pharmacokinetic*, 34, 503-515, 1998.

Southgate, V.R., Rollinson, D., Tchuem Tchuente, L.A. and Hagan, P., Towards control of schistosomiasis in sub-Saharan Africa, *Journal of Helminthology*, 79, 181-185, 2005.

Staudt, U., Schmahl, G., Blaschke, G., and Mehlhorn, H., Light and scanning electron microscopy studies on the effects of the enantiomers of praziquantel and its main metabolite on *Schistosoma mansoni* in vitro, *Parasitology Research*, 78, 392-7, 1992.

Steinmann, P., Keiser, J., Bos, R., Tanner, M. and Utzinger, J., Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk, *Lancet Infectious Disease*, 6, 411-25, 2006.

Stettler M., Rossignol JF., Fink R., Walker M., Gottstein B., Merli M., Theurillat R., Thormann W., Dricot E., Segers R., and Hemphill A., Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity, *International Journal for Parasitology*, 34(5),615-24,2004.

Strickley, R.G., Solubilizing excipients in oral and injectable formulations, *Pharmacy Research*, 21, 201-230, 2004.

Suresh, G., Manjunath, K., Venkateswarlu, V., Satyanarayana, and V., Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. *AAPS Pharmaceutical Sciences and Technology*, 8, 24, 2007.

Swaminathan, S., Pastoro, L., Serpe, L., Trotta, F., Vavia, P., and Aquilano, D., Cyclodextrin-based nanosponges encapsulating camptothecin, physicochemical characterization, stability and cytotoxicity, *European Journal of Pharmaceutics and Biopharmaceutics*, 74, 193–201, 2009.

Swaminathan, S., Vavia, P., Trotta, F., and Torne, S., Formulation of Betacyclodextrin based nanosponges of Itraconazole, *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, 57, 89–94, 2007.

Tanaka, M., Ohmae, H., Utsunomiya, H., Nara, T., Irie, Y., and Yasuraoka, K., A comparison of the antischistosomal effect of levo- and dextro-praziquantel on *Schistosoma japonicum* and *S. mansoni* in mice, *American Journal of Tropical and Medical Hygiene*, 41, 198-203, 1989.

Taylor, D.H., and Morris, D.L., Combination chemotherapy is more effective in postspillage prophylaxis for hydatid disease than either albendazole or praziquantel alone, *British Journal of Surgery*, 76, 954, 1989.

Thomas H., and Gönner R., The efficacy of praziquantel against cestodes in animals, *Z Parasitenk*, 52(2), 117–127, 1977.

Thompson RC., Reynoldson JA., and Ridler CR., Praziquantel adversely affects protoscoleces of *Echinococcus granulosus* in vitro, *Journal of helminthology*, 60, 279–286, 1986.

Tiyaboonchai, W., Tungpradit, W., and Plianbangchang, P., Formulation and characterization of curcuminoids loaded solid lipid nanoparticles, *International Journal of Pharmaceutics*, 337, 299–306, 2007.

Torne, S.J., Ansari, K.A., Vavia, P.R., Trotta, F., and Cavalli, R., Enhanced oral Paclitaxel bioavailability after administration of Paclitaxel loaded nanosponges, *Drug Delivery*, 17, 419-425, 2010

Trotta, F., and Tumiatti, W., WO 03/085002 (2003)

Trotta, M., Debernardi, F., and Caputo, O., Preparation of solid lipid nanoparticles by a solvent emulsification diffusion technique, *International Journal of Pharmaceutics*, 257, 153-160, 2003.

Urrea-París, M., Casado, N., Moreno, M. and Rodriguez-Caabeiro, F., Chemoprophylactic praziquantel treatment in experimental hydatidosis, *Parasitology Research*, 87, 510–512, 2001.

Vasir, J.K., Tambwekar, K., and Garg, S., Bioadhesive microspheres as a controlled drug delivery system, *International Journal of Pharmaceutics*, 255 (1-2), 13-32, 2003.

Venkatesan, N., Uchino, K., Amagase, K., Ito, Y., Shibata, N., and Takada, K., Gastrointestinal patch system for the delivery of erythropoietin, *Journal of Control Release*, 111, 19-26, 2006.

Venkateshwarlu, V., and Manjunath, K., Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles, *Journal of Control Release*, 95, 627-638, 2004.

Vermund, S.H., Bradley, D.J. and Ruiz-Tiben, E., Survival of *Schistosoma mansoni* in the human host: Estimates from a community-based prospective study in Puerto Rico, *American Journal of Tropical Medicine and Hygiene*, 32, 1040, 1983.

Vivek, K., Reddy, H. and Murthy, R. S. R., Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles, *AAPS Pharmaceutical Science and Technology*, 8, 16-24, 2007.

Wasan, K.M., Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. *Drug Development and Industrial Pharmacy*, 27, 267-276, 2001.

Windbergs, M., Strachan, C.J., and Kleinebudde, P., Understanding the solid state behavior of triglyceride solid lipid extrudates and its influence on dissolution, *European Journal of Pharmaceutics and Biopharmaceutics*, 71, 80-87, 2009.

Wissing, S.A., Kayser, O., and Muller, R.H., Solid lipid nanoparticles for parenteral drug delivery. *Adv. Drug Delivery Review*, 56, 1257-1272, 2004.

World health organization, First WHO report on neglected tropical diseases, 2013, Available at:http://www.who.int/neglected_diseases/en/ (Accessed December, 2013)

World health organization, WHO Model List of Essential Medicines, 18th list, 2013, Available at:<http://www.who.int/medicines/publications/essentialmedicines/en/index.html> (Accessed Nov. 2013)

Wu, M.H., Wei, C.C., Xu, Z., Yuan, H.C., Lian, W.N., Yang, Q.J., Chen, M., Jiang, Q.W., Wang, C.Z. and Zhang, S.J., Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica, *American Journal of Tropical Medicine and Hygiene*, 45, 345–349, 1991.

Xiao, S.H. and Catto, B.A., Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on *Schistosoma mansoni*, *Journal of Infectious Disease*, 159, 589–592, 1989.

Xiao, S.H., Catto, B.A., and Webster, L.T., Effects of praziquantel on different developmental stages of *Schistosoma mansoni* in vitro and in vivo, *Journal of Infectious Disease*, 151, 1130–1137, 1985.

Xiao, S.H., Catto, B.A., and Webster, L.T., Jr, Quantitative determination of praziquantel in serum by high performance liquid chromatography, *Journal of Chromatography*, 275, 127–132, 1983.

Xiao, S.H., You, J.Q., Mei, J.Y., and Jiao, P.Y., Early treatment of schistosomal infection with praziquantel in mice. *Acta Tropica*. 14, 533–538, 1993.

Xie, S., Pan, B., Wang, M., Zhu, L., Wang, F., Dong, Z., Wang, X., and Zhou, W., Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles, *Nanomedicine (Lond)*, 5, 693-701, 2010.

Yadav, AK., Temjenmongla, Anticestodal activity of *Houttuynia cordata* leaf extract against *Hymenolepis diminuta* in experimentally infected rats, *Journal of Parasitic Diseases*, 35(2): 190–194, 2011.

Yang, L., Geng, Y., Li, H., Zhang, Y., You, J., and Chang Y., Enhancement the oral bioavailability of praziquantel by incorporation into solidlipidnanoparticles., *Pharmazie.*, 64,86-89, 2009.

Yoshikawa, H., Muranishi, S., Kato, C., and Sezaki, H., Bifunctional delivery system for selective transfer of Bleomycin into lymphatics via enteral route, *International Journal of Pharmaceutics*, 8, 291-302, 1981.

Zajac, A.M., Developments in the treatment of gastrointestinal parasites of small animals. *Vetrinary Clinics of North American: Small Animal Practice*, 23, 671-681, 1993.

Zhang, Y.C., and Benet, L.Z., The gut as a barrier to drug absorption combined role of cytochrome P450 3A and P-glycoprotein, *Clinical Pharmacokinetic*, 40, 159–168, 2001

Zhang, Z., Gao, F., Bu, H., Xiao, J., and Li, Y., “Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats,” *Nanomedicine: Nanotechnology, Biology and Medicine*, vol.8, pp.740–747, 2012.